Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)
| Market Cap | $38.86M-87.3% |
| Revenue (ttm) | $0 |
| Net Income | -$19.13M+55.7% |
| EPS | -$0.32+56.2% |
| Shares Out | 60.36M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 733,834 |
| Open | $0.61 |
| Previous Close | $0.63 |
| Day's Range | $0.59 - $0.66 |
| 52-Week Range | $0.53 - $5.93 |
| Beta | 1.29 |
| Analysts | Buy |
| Price Target | $9.67(+1402.02%) |
| Earnings Date | Feb 26, 2027 |
About ALDX
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Aldeyra Therapeutics, Inc. Stock Analysis — InsiderScore
Aldeyra Therapeutics, Inc. scored higher than 87% of companies evaluated by InsiderBuying, and ranked 10th out of 99 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Aldeyra Therapeutics, Inc. bought $135.4K of stock across 2 purchases in the last 90 days, the largest of them $128.9K.
The average purchase added about 100% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
2 firms rating ALDX in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 26, 2027Earnings report
$ALDX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ALDX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ALDX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ALDX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ALDX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ALDX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ALDX
| VTIVanguard Morningstar Total Stock Market ETF | $2.19M |
| VXFVanguard Extended Market ETF | $705.62K |
| VHTVanguard Health Care ETF | $206.24K |
| IWCiShares Micro-Cap ETF | $117.05K |
| PRFZInvesco RAFI US 1500 Small-Mid ETF | $64.64K |
| QQQSInvesco NASDAQ Future Gen 200 ETF | $51.03K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from ALDX’s recent data — informational, not investment advice